Showing 1 to 10 of 26
| Title | Reference number | Reference number sort | Published | Published date sort | Last updated | Last updated sort |
|---|---|---|---|---|---|---|
| Safeguarding adults in care homes | Reference number:NG189 | NG00189 | Published:26 February 2021 | 20210226 | Last updated:26 February 2021 | 20210226 |
| Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis | Reference number:ES35 | ES00035 | Published:24 February 2021 | 20210224 | Last updated:24 February 2021 | 20210224 |
| Metreleptin for treating lipodystrophy | Reference number:HST14 | HST00014 | Published:24 February 2021 | 20210224 | Last updated:24 February 2021 | 20210224 |
| Filgotinib for treating moderate to severe rheumatoid arthritis | Reference number:TA676 | TA00676 | Published:24 February 2021 | 20210224 | Last updated:24 February 2021 | 20210224 |
| Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma | Reference number:TA677 | TA00677 | Published:24 February 2021 | 20210224 | Last updated:24 February 2021 | 20210224 |
| Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | Reference number:TA678 | TA00678 | Published:24 February 2021 | 20210224 | Last updated:24 February 2021 | 20210224 |
| Dapagliflozin for treating chronic heart failure with reduced ejection fraction | Reference number:TA679 | TA00679 | Published:24 February 2021 | 20210224 | Last updated:24 February 2021 | 20210224 |
| COVID-19 rapid evidence summary: Tocilizumab for COVID-19 | Reference number:ES33 | ES00033 | Published:15 January 2021 | 20210115 | Last updated:24 February 2021 | 20210224 |
| Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | Reference number:TA673 | TA00673 | Published:17 February 2021 | 20210217 | Last updated:17 February 2021 | 20210217 |
| Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) | Reference number:TA674 | TA00674 | Published:17 February 2021 | 20210217 | Last updated:17 February 2021 | 20210217 |